Top Markets
#1 CyberDEX CyberDEX +391.95%
#2 OVERTAKE OVERTAKE +58.99%
#3 Clearpool Clearpool +25.94%
#4 Playnance Playnance +23.93%
#5 deBridge deBridge +22.97%
#6 B3 (Base) B3 (Base) +20.83%
#7 Nillion Nillion +19.56%
#8 AUKI AUKI +19.09%
#9 Codatta Codatta +17.25%
#10 龙虾 (Lobster) 龙虾 (Lobster) +17.03%
Coin of the day
CyberDEX CyberDEX
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rangering i aksjer #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Aksjekurs
$0.00185055
Markedsverdi
$48.29K
Endring (1 dag)
-3.55%
Endring (1 år)
30.31%
Land
GB
Handel Nuformix plc (NFX)

Kategori

Healthcare
Antall utestående aksjer for Nuformix plc (NFX)
Antall utestående aksjer per March 2026: 2.12B
Ifølge Nuformix plc sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 2.12B. Ved slutten av September 2024 hadde selskapet 787.01M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Nuformix plc (NFX) fra 2014 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 2.12B 27.71%
2025 1.66B 111.05%
2024 787.01M 9.39%
2023 719.46M 20.22%
2022 598.45M 3.07%
2021 580.63M 21.71%
2020 477.06M 3.54%
2019 460.75M 23.34%
2018 373.55M 290.13%
2017 95.75M 59.34%
2016 60.09M 0.00%
2014 0.00 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -88.03%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -81.33%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -77.42%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -97.07%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH